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Abstract Glutathione S-transferase (GST) enzymes are 
known to metabolize tobacco-related carcinogens. Previous 
studies on the association of functional polymorphisms of 
GST genes with esophageal squamous cell carcinoma have 
yielded conﬂicting but overall null results. A few studies of 
esophageal adenocarcinoma were likewise conﬂicting, but 
the scarcity of data is striking. We aimed to study associa­
tions of the GSTM1 and GSTT1 null deletion polymorphisms 
as well as the GSTP1 Ile105Val polymorphism with risks for 
esophageal and gastric cardia cancers. DNA was prepared 
from 96 and 79 cases of esophageal adenocarcinoma and 
squamous cell carcinoma, respectively, 126 cardia cancer 
cases, and 471 population-based controls. Pyrosequencing 
typed the GSTP1 Ile105Val polymorphism, while multiplex 
PCR detected GSTM1 and GSTT1 deletions. Logistic 
regression modeling estimated odds ratios (ORs) with 95% 
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conﬁdence intervals (CIs). None of the studied polymor­
phisms were related to the risk of esophageal adenocarci­
noma, but the variant GSTP1 Val105 allele was associated 
with an increased risk of esophageal squamous cell carci­
noma (OR = 1.7; 95% CI 1.0–2.9) and tended to be weakly, 
positively linked to cardia cancer (OR = 1.4; 95% CI 0.9– 
2.1). Finally, we performed a meta-analysis and found that 
GSTP1 polymorphism seems to be associated with the risk of 
esophageal squamous cell carcinoma among Caucasian 
population (OR = 1.4; 95% CI 1.0–2.2; p value for hetero­
geneity test 0.34). 
Keywords Glutathione S-transferase  GSTT1  
GSTM1  GSTP1  Esophageal cancer  
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Introduction 
Since the 1970s, the Western world, including Sweden, has 
faced a rise in esophageal adenocarcinoma incidence of 
almost epidemic proportions [1, 2]. Although increasing 
prevalence of gastroesophageal reﬂux and overweight/ 
obesity are the postulated reasons, the exact underlying 
mechanisms remain unclear. While genetic predisposition 
per se is highly unlikely to contribute importantly to such 
rapid changes in incidence, interactions with environmental 
exposures may amplify the effects of the latter in susceptible 
individuals, and perhaps explain some of the remarkable 
geographic and ethnic differences in the descriptive epide­
miology of esophageal cancer. 
Human cytosolic glutathione S-transferases (GSTs) are 
phase II metabolizing enzymes that detoxify free radicals 
and other carcinogens; especially, tobacco substrates [3]. 
GSTP1, GSTM1, and GSTT1 are members of the GST super 
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family genes found to be polymorphic in humans [3]. There 
is a single nucleotide polymorphism (SNP) (rs1695) of the 
GSTP1 gene that leads to substitution of isoleucine (Ile) by 
valine (Val) at amino acid position 105, altering the con­
jugating activity of some substrates [4]. The Val variant 
has been linked to increased risks for bladder, testicular, 
and prostate cancers [5]. GSTM1 and GSTT1 null geno­
types, found in, respectively, 42–60% and 13–26% of the 
Caucasian population worldwide [6], have been implicated 
as risk factors for several human malignancies, including 
gastric, colorectal, and lung cancers [7–12], although null 
or even inverse associations were also reported [7, 11, 13– 
16]. Although GSTs are expressed in almost all organs, 
their expression, particularly GSTP1, in the esophagus is 
abundant. 
The GSTP1 Ile105Val polymorphism has been evalu­
ated in relation to esophageal cancer risk (mostly squamous 
cell carcinoma) in 15 studies [17–25], but the results were 
highly variable with odds ratios ranging between 0.1 and 
4.6 among hetero- or homozygous carriers of the variant 
Val allele, relative to homozygotes for the wild type Ile 
allele. The summary estimate of relative risk in a meta-
analysis of seven of these studies was 1.01 (95% CI 0.60– 
1.70) [23]. The highest odds ratio (4.6; 95% CI 1.5–14.6) 
was noted for Dutch patients with esophageal adenocarci­
noma, and the other studies that could evaluate esophageal 
adenocarcinoma separately showed point estimates 
between 0.9 and 1.9 [17, 18, 20, 24–26]. The results of 
epidemiological investigations into the role of the GSTM1 
deletion polymorphism are not very convincing; among 20 
published studies (mainly from China and Japan but also 
from India, the Netherlands, France, US, and Canada) [19– 
24, 27, 28], the odds ratio for esophageal cancer among 
individuals with the GSTM1 0/0 genotype varied between 
0.4 and 13.2, with a summary estimate of 1.07 (95% CI 
0.76–1.51) among 12 studies included in a meta-analysis 
[23]. Similarly, with only one borderline exception [22], 12 
studies of the importance of the GSTT1 0/0 deletion 
polymorphism, conducted in China, India, France, US, and 
Canada, were consistently negative [17, 19–24], and the 
summary relative risk estimate among six of these studies 
was 0.99 (95% CI 0.80–1.22). Interestingly, though the 0/0 
genotype was observed signiﬁcantly less often in 26 French 
patients with esophageal adenocarcinoma than in 130 
control subjects (odds ratio 0.1), but this inverse associa­
tion was not conﬁrmed by any other investigators who 
studied this histological type of esophageal cancer [19, 20, 
24, 26, 29]. However, due to the rarity of esophageal 
adenocarcinoma, most previous studies have had low 
statistical power to detect moderately strong associations, 
and positive ﬁndings need to be replicated in larger 
studies. Moreover, few of the previous studies were truly 
population-based. 
The present population-based case–control study in 
Sweden is, to our knowledge, the largest study to date 
addressing the association of genetic polymorphism in 
GSTM1 and GSTT1 genes with esophageal adenocarci­
noma and the second largest study investigating the link 
between the Ile105Val polymorphism and this neoplasm. 
We also studied the association with esophageal squamous 
cell carcinoma and gastric cardia cancers. 
Subjects and methods 
Patients 
The study design and characteristics of the participants in 
the Swedish Esophageal and Cardia Cancer Study (SECC) 
have been described in detail previously [30, 31]. Brieﬂy, 
during 1995 through 1997 all newly diagnosed native 
Swedish patients with esophageal adenocarcinoma or car­
dia cancer and half of the patients with esophageal squa­
mous cell carcinoma (born on even dates) were recruited. 
Cancer patients were accrued via a comprehensive orga­
nization with contact persons at all 195 departments in 
entire Sweden. Controls were cancer-free native Swedes 
who were selected randomly from the entire Sweden, fre­
quency matched on age (in 5 year categories) and sex 
distribution among the esophageal adenocarcinoma cases. 
The controls were selected through the use of computerized 
national population register, which is continuously upda­
ted. Information about demographic characteristics and 
several risk factors including smoking habits were col­
lected from both cases and controls by means of face-to­
face interviews conducted by professional interviewers. 
Genotyping 
Donated whole blood samples were stored at -70�C until 
DNA was extracted. Genomic DNA was isolated using 
Gentra Puregene kit (Gentra Systems, Minneapolis, MN, 
USA). Blinding to the case/control status was maintained 
throughout the genotyping and analyses. 
GSTP1 
We performed genotyping of GSTP1 using Pyrosequenc­
ing, a real-time high throughput SNP scoring technique in 
which an enzyme cascade system provides a positive or a 
negative result. The results were validated during the 
genotyping through real sequence proof reading, which is 
an integrated part of the Pyrosequencing technology. 
Primers for PCR ampliﬁcation and Pyrosequencing were 
50-TAGTTTGCCCAAGGTCAAG-30 and 50-AGCCAACC 
TGAGGGGTAAG-30. The PCR product was ampliﬁed in a 
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total volume of 25 ll reaction mixture containing PCR 
buffer, 10 ng genomic DNA, 1.5 mM MgCl2, 0.15 mM 
each dNTP, 0.2 lM each primer, and 1.0 unit AmpliTaq 
Gold DNA polymerase (Applied Biosystem, USA). After 
initial denaturation for 2 min at 95�C, the DNA was 
ampliﬁed by 35 cycles of 40 s at 94�C, 40 s at 58�C, and 
40 s at 72�C. For Pyrosequencing, biotinylated PCR prod­
ucts (25 ll) were immobilized on streptavidin-coated 
sepharose beads (Streptavidin Sepharose HP, Amersham 
Bioscience) in 40 ll binding buffer (10 mM Tris HCl (pH 
7.6), 2 M NaCl, 1 mM EDTA, 0.1% Tween 20) and 15 ll 
H2O for 5 min at room temperature. The products were then 
passed through the Vacuum Prep Worktable to prepare the 
single-stranded DNA (Biotag, Uppsala, Sweden). Samples 
were released in 96-well plates, containing annealing buffer 
and sequencing primer, and heated at 85�C for 2 min, and 
then cooled down to room temperature. The Pyrosequencing 
was performed on an automated 96-well PSQ 96 instrument 
using enzyme and substrates from the PSQ 96 SNP reagent 
kit (Biotage AB). 
GSTM1 and GSTT1 
A multiplex PCR method was used to detect the null geno­
type of GSTM1 and GSTT1 as described previously with 
slight modiﬁcations. Brieﬂy, GSTM1 and GSTT1 primers as 
well as primers of b-globin gene as positive control were all 
ampliﬁed in each tube. GSTM1 was ampliﬁed using primers 
corresponding to the 30-coding region of the human GST: 
50-AACTCCCTGAAAAGCTAAAG-30 and 50-GTTGGG 
AAATATACGGTG-30 , and the primers coding for the 
human GSTT1 were 50-TTCCTTACTGGTCCTCACATC 
TC-30 and 50-TCACCGGATCATGGCCAGCA-30. We also 
ampliﬁed b-globin as positive control using 50-CAACTTCA 
TCCACGTTCACC-30 and 50-GAAGAGCCAAGGACAG 
GTAC-30 primers. PCR was carried out in a 25 ll mixture 
containing PCR buffer, 1.5 mM MgCl2, 12.5 ng genomic 
DNA, and 2.0 ll of each primer, 1.25 ll DSMO, 1.25 ll 
dNTP, 5.25 ll H2O, 1.25 unites Taq polymerase, and 2.5 ll 
(12.5 ng) DNA. Ampliﬁcation was achieved by 35 cycles of 
1 min at 94�C, 1 min at 59�C, and 1 min at 72�C. Ampliﬁed 
products were resolved on a 3% Nusieve agarose gel to 
determine the presence or absence of 219 bp GSTM1, 459 bp 
GSTT1 products, or 270 bp b-globin. In the presence of 
b-globin band, the absence of either GSTM1 or GSTT1 bands 
was considered null genotype exclusively. A negative PCR 
reaction was performed for each 96-well plate. Moreover, all 
samples with a faint band of b-globin were repeated. Finally, 
in a quality assessment, we repeated the genotyping among 
5% of randomly selected individuals. Comparing the quality 
assessment and main data, it was showed that 97% of the 
genotypes were reproducible. 
Statistical analyses 
We determined allele and genotype frequencies for GSTP1 
and tested for deviations from the Hardy–Weinberg equi­
librium among controls using the Chi-square method with 
one degree of freedom. Using unconditional logistic 
regression, we estimated odds ratios with 95% conﬁdence 
intervals (CIs). We considered adjustments for established 
risk factors of esophageal cancer including smoking status 
(never, former or current smokers 2 years before interview), 
fruit and vegetable intake (in three categories), alcohol 
consumption (total amount in grams of pure alcohol derived 
from all types of alcoholic beverages, categorized into four 
levels), BMI (in quartiles), reﬂux (occurring at least once 
per week), socioeconomic status (reﬂected by number of 
years of formal education categorized into three levels). 
However, chi-square tests showed no associations between 
GST polymorphisms and these risk factors. Moreover, 
adjustments in the regression models did not change the 
gene-cancer odds ratios materially. Therefore, we retained 
only the frequency matching variables—sex and age (in 
5 years age bands)—in the ﬁnal models. We attempted to 
explore gene–environment interactions between GST 
polymorphisms and smoking status (ever/never smoking); 
but due to the small sample size, we had insufﬁcient power 
to detect clinically important interactions. Based on the 
biological understanding of the effect of GST enzymes on 
tobacco-speciﬁc carcinogens, we still performed supple­
mentary analyses stratiﬁed by smoking status. We used 
STATA (Release 9.1) for statistical analyses. 
The study was approved by the regional ethics com­
mittee at Uppsala University. Individual informed consent 
was obtained before interview and also for subsequent 
genotyping from all surviving participants. 
Meta-analyses 
In order to shed further light on association between GST 
polymorphisms and esophageal cancer, we performed a 
meta-analysis from reported studies. We systematically 
searched PUBMED and WEB of Science to ﬁnd the 
available reports on this subject. However, the meta-anal­
yses were restricted to the studies reported from Caucasian 
population. We used ﬁxed and random effect modeling to 
estimate the summary Odds ratios. 
Results 
We managed to interview 189 incident cases of esophageal 
adenocarcinoma, 167 with squamous cell carcinoma, 
and 262 with cardia cancer, constituting, respectively, 88, 
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73, and 84% of all eligible cases occurring in the study 
base. Of 1,128 randomly selected frequency-matched 
control subjects, 820 (73%) agreed to be interviewed. DNA 
samples were obtained from 303 cases and 488 controls. 
The main reason for missing samples among cases was that 
the clinicians forgot to collect whole blood, while failure to 
appear at the local health center was the main reason 
among controls. Only one living case and ﬁve living con­
trols refused subsequent genotyping, and another thirteen 
living controls who could not be traced for their second 
informed consent were excluded from the present study. 
Finally, 96 and 79 patients with esophageal adenocarci­
noma and squamous cell carcinoma, respectively, 126 
patients with cardia cancer, and 471 controls were included 
in this study (Table 1). They constituted about 49% and 
57% of all interviewed cases and controls, respectively. 
The distribution of participants by place of residence, 
gender, smoking, alcohol consumption, and socioeconomic 
status was similar to those from the entire study [31]. 
Smoking habits were more widespread among esophageal 
squamous cell carcinoma patients than any other group 
(Table 1). 
Among controls, the frequency of GSTP1 variant allele 
was 31% and the genotype distributions did not deviate 
from Hardy–Weinberg equilibrium (p = 0.2). GSTT1 and 
GSTM1 null genotypes were observed among 16% and 
49% of controls. We did not ﬁnd any association between 
any of the studied GST gene polymorphisms and the risk of 
esophageal adenocarcinoma (Table 2). However, we 
observed a 70% excess risk of esophageal squamous cell 
carcinoma (OR = 1.7; 95% CI 1.0–2.8) and a non-signif­
icant 40% excess risk of cardia cancer (OR = 1.4; 95% CI 
0.9–2.1) among carriers of the GSTP1 variant Val105 allele 
(homozygotes or heterozygotes). Further stratiﬁcation 
showed that excess risks were mainly driven by individuals 
who were homozygotes for the variant allele, both in 
esophageal squamous cell carcinoma (OR = 2.4; 95% CI 
1.0–5.0) and cardia cancer (OR = 2.3; 95% CI 1.3–4.5). 
Furthermore, a restriction to ever-smokers unveiled stron­
ger and statistically signiﬁcant associations of GSTP1 
variant genotypes with esophageal squamous cell carci­
noma and cardia cancers (Table 3), while there was no 
association among non-smokers (data not shown). The 
interaction did not attain statistical signiﬁcance, though. 
Finally, the prevalence of the GSTT1 null genotype tended 
to be lower among patients with esophageal squamous cell 
carcinoma (OR = 0.5; 95% CI 0.2–1.2) and cardia cancer 
(OR = 0.6; 95% CI 0.3–1.1) than among controls, but the 
inverse associations were not statistically signiﬁcant. 
The results of our meta-analyses on Western studies, 
including our own, are tabulated in Table 4. The summary 
odds ratio for association between the GSTP1 Ile105Val 
Table 1 Characteristics of 301 
cancer patients and 471 control 
Controls Esophageal 
adenocarcinoma 
Esophageal squamous 
cell carcinoma 
Gastric cardia 
cancer 
subjects who were interviewed 
and provided DNA samples Total number (%) 471 (100) 96 (100) 79 (100) 126 (100) 
Male (%) 389 (82.6) 86 (89.6) 56 (70.9) 110 (87.3) 
Smoker (%) 270 (57.3) 66 (68.8) 69 (87.3) 112 (88.9) 
Median age (years) 69 68 64 66 
Table 2 Association of glutathione S-transferase genes with esophageal and gastric cardia cancers, the Swedish Esophageal and Cardia Cancer 
Study (SECC) study, 1994–1997 
Genotypes Esophageal adenocarcinoma Esophageal squamous cell Gastric cardia cancer 
carcinoma 
No. of controls No. of cases OR (95% CI)b No. of controls OR (95% CI)b No. of cases OR (95% CI)b 
GSTP1a wild type (Ile/Ile) 208 44 Reference 26 Reference 47 Reference 
GSTP1 variant (Ile/Val, Val/Val) 245 50 1.0 (0.6–1.5) 52 1.7 (1.0–2.9) 75 1.4 (0.9–2.1) 
Heterozygote (Ile/Val) 207 42 1.0 (0.6–1.6) 42 1.6 (0.9–2.8) 56 1.2 (0.8–1.9) 
Homozygote (Val/Val) 38 8 1.0 (0.4–2.3) 10 2.4 (1.0–5.0) 19 2.3 (1.3–4.5) 
GSTMa active 230 52 Reference 35 Reference 54 Reference 
GSTM1 null (deletion) 239 43 0.9 (0.5–1.3) 42 1.3 (0.8–2.1) 70 1.4 (0.9–2.1) 
GSTT1a active 394 80 Reference 70 Reference 111 Reference 
GSTT1 null (deletion) 76 15 1.0 (0.5–1.8) 7 0.5 (0.2–1.2) 13 0.6 (0.3–1.1) 
a We could not amplify 25 samples while genotyping GSTP1, and 7 samples while genotyping GSTT1 and GSTM1, and they were excluded from 
the analyses 
b OR Odds ratio, adjusted for sex and age 
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Table 4 Summary of epidemiological studies on GST polymorphisms and esophageal cancer conducted among Western populations 
Study GSTM1 (deletion versus active) GSTT1 (deletion versus active)	 GSTP1 Ile105Val SNP (Val/Val ? Ile/Val 
versus Ile/Ile) 
Cases Controls OR (95% CI) Cases Controls OR (95% CI) Cases Controls OR (95% CI) 
Esophageal adenocarcinoma 
t	 tvan Lieshout et al. [29]a 12/9 128/119 1.2 (0.5–3.1) 4/17 49/198 1.0 (0.3–3.0) 16/5 101/146 4.6 (1.5–15.0)t 
tCasson et al. [26]b 26/19 25/20 1.1 (0.5–2.5)§ 8/37 12/33 0.6 (0.2–1.6)§ 26/19 19/26 1.9 (0.8–4.7)
Abbas et al. [17]c 12/13 59/61 1.0 (0.4–2.4)§ 1/25 30/85 0.1 (0.0–0.6)§ 15/10 65/59 1.2 (0.5–3.0)§ 
Casson et al. [19]b 34/22 54/41 1.2 (0.6–2.3)t 14/42 15/80 1.8 (0.8–4.0)t 38/18 55/40 1.5 (0.8–3.1)t 
Murphy et al. [25]d – – – – – – 124/83 137/86 0.9 (0.6–1.4)§ 
Wideroff et al. [24]e 37/30 121/87 1.0 (0.6–1.7)§ 8/59 35/173 0.8 (0.3–1.8)§ 35/32 115/91 1.0 (0.5–1.7)t 
Present studyf 43/52 239/230 0.9 (0.6–1.3)§ 15/80 76/394 1.0 (0.5–1.8)§ 50/44 245/208 1.0 (0.6–1.5)§ 
Overall 164/145 626/558 1.0 (0.8–1.2) 50/260 217/963 0.9 (0.5–1.4) 304/211 737/656 1.2 (0.9–1.6) 
p value for heterogeneity 0.9 0.1 0.2 
Esophageal squamous cell carcinoma 
van Lieshout et al. [29]a 5/8 128/119 0.6 (0.2–1.8)t 2/11 49/198 0.7 (0.2–3.4)t 8/5 101/146 2.3 (0.7–8.4)t 
Abbas et al. [17]c 27/16 59/61 1.8 (0.9–3.8)§ 13/31 30/85 1.0 (0.5–2.3)§ 24/21 65/59 1.0 (0.5–1.9)§ 
Present studyf 42/35 239/230 1.3 (0.8–2.2)§ 7/70 76/394 0.5 (0.2–1.2)§ 52/26 245/208 1.7 (1.0–2.9)§ 
Overall 74/59 426/410 1.3 (0.8–2.1) 23/112 155/677 0.7 (0.4–1.3) 84/52 411/413 1.4 (1.0–2.2) 
p value for heterogeneity 0.3 0.5 0.3 
Random effect modeling was used for meta-analyses 
OR Odds Ratio, 95% CI 95% conﬁdence interval 
a	 tThe Netherlands, b Canada, c France, d Ireland, e US, f Sweden, crude, § adjusted 
polymorphism and the esophageal adenocarcinoma was 1.2 
(95% CI 0.9–1.6), while the summary odds ratios for the 
GSTT1 and GSTM1 deletion polymorphisms showed null 
results. 
Although number of studies among Caucasians popu­
lation is limited, meta-analyses of the three available 
studies, including our study, revealed a borderline signiﬁ­
cant association between the GSTP1 Val105 genotype and 
esophageal squamous cell carcinoma in Caucasian popu­
lations (OR = 1.4; 95% CI 1.0–2.2, p value for heteroge­
neity: 0.34). 
Discussion 
In this nation-wide population-based case–control study, 
neither the GSTM1 or GSTT1 deletion polymorphisms, nor 
the GSTP1 Ile105Val SNP, were associated with risk of 
esophageal adenocarcinoma. On the other hand, our data 
suggest a positive association between the presence of the 
variant GSTP1 Val105 allele and the risk of esophageal 
squamous cell carcinoma, with the highest relative risks 
seen among homozygous carriers and among smokers. 
Strengths of this study include the population-based 
design in an ethnically homogenous native Swedish 
population, comprehensive face-to-face interviews with all 
cases and controls, case ascertainment designed to capture 
all incident cases—not only surgically treated ones—and 
prospective careful classiﬁcation of every incident case. 
However, although the participation rate was high in the 
interview part, the proportion from whom we obtained 
DNA was no more than approximately 50% among the 
cases and 60% among the controls. As the failure to obtain 
blood samples among cases could largely be attributed to 
inattention among the hospital staff rather than to patient 
characteristics, it is unlikely that the non-participation 
would systematically be linked to the studied GST geno­
types. Among the controls, the frequency of missing blood 
samples was less but the scope for self-selection was 
greater. Fortunately, the cases and controls who donated 
blood and participated in the present analysis were similar 
to all those who underwent interviews in all investigated 
background variables [31] and given the ethnic homoge­
neity of the population it seems unlikely that the exclusions 
due to missing blood samples have importantly biased the 
studied genetic associations. The allele frequencies for all 
of the studied polymorphisms were similar to those 
reported from Caucasian populations [32], and the GSTP1 
genotype distribution was in Hardy–Weinberg equilibrium. 
However, the study power—despite the fact that this is one 
123
 
2037 Cancer Causes Control (2009) 20:2031–2038 
of the largest studies in a Western population—was 
insufﬁcient for detecting small-to-moderate genetic main 
effects, and clearly inadequate for any statistical assess­
ment of gene–environment interactions. 
Seven previous studies have analyzed esophageal ade­
nocarcinoma separately; totally, these studies included 432 
patients (range 9–207). The only such study that was not 
based on Western Caucasian populations was an Indian 
study with no more than nine veriﬁed adenocarcinoma 
cases [20]. Among studies on Caucasian population, the 
only signiﬁcant ﬁndings were a 4.6-fold risk of esophageal 
adenocarcinoma among Dutch carriers of the variant 
GSTP1 Val105 allele, and a 90% risk reduction among 
French individuals who had the GSTT1 null genotype. The 
overall results of previous studies on GST polymorphisms 
and esophageal adenocarcinoma risk, with the possible 
exception of the GSTT1 null genotype, were in line with 
our null results. However, our and previous studies alike 
were insufﬁciently powered to detect moderately increased 
relative risks. 
The risk elevation for esophageal squamous cell carci­
noma and the trend toward higher risk for cardia cancer, 
linked to the GSTP1 Val105 allele in our study, gets little 
support in the published literature, both that concerned with 
Caucasian populations (based on limited data) [17, 29] and 
that investigating Asian subjects [23]. It might be worth 
noting, though, that the point estimate for cardia cancer 
among carriers of the variant allele in a US study [24] was 
1.15 (not signiﬁcant) and among homozygotes 1.46 (not 
signiﬁcant). 
Although number of studies among Caucasians popu­
lation is limited, meta-analyses of the three available 
studies, including our study, revealed a borderline signiﬁ­
cant association between the GSTP1 Val105 genotype and 
esophageal squamous cell carcinoma in Caucasian popu­
lations (OR = 1.4; 95% CI 1.0–2.2). Given OR: 1.01 in the 
published meta-analysis mainly encompassing seven Asian 
studies [23], a heterogeneity in the effect of this poly­
morphism exists between Asian and Western population. 
GSTP1 plays important role in metabolism and detoxiﬁ­
cation of many carcinogenic xenobiotics [33, 34]. GSTP1 
is expressed in the esophagus, and its Ile105Val polymor­
phism is functional so that the catalytic effect of the variant 
enzyme for 1-chloro-2,4-dinitrobenzene—the standard 
substrate for GST enzymes—is about threefold to fourfold 
lower than the wild type protein [35]. On the other hand, 
the variant of enzyme more effectively metabolizes the diol 
epoxides of polycyclic aromatic hydrocarbons (PAHs), a 
ubiquitous tobacco-related carcinogen. Because of this 
metabolic activity, GSTP1 is expected to play protective 
role against carcinogenicity of the PAHs. Epidemiological 
studies have shown that GSTP1 polymorphisms seem to be 
more associated with tobacco-related cancers [33]. The 
association of smoking—the products of which are 
importantly metabolized by the GST genes—and the risk 
of esophageal squamous cell carcinoma tends to be stron­
ger in Caucasian populations than among Asians [23, 33], 
so differences in main effects of GSTP1 variant alleles in 
these two populations might be plausible. Clearly, more 
data from studies among Caucasians are needed. 
We also found a borderline inverse association between 
carriage of the GSTT1 null genotype and cardia cancer risk, 
particularly among smokers. This was not observed in the 
previous studies of this particular relationship [17, 21, 24] 
and not in the combined literature about the GSTT1 dele­
tion polymorphism and gastric cancer overall [7]. There­
fore, we believe that the seeming protection was a chance 
ﬁnding. 
Val105In conclusion, carriage of the variant GSTP1 
allele might be linked to the risk of esophageal squamous 
cell carcinoma, with a tendency for interaction with 
tobacco smoking. The association seems to be pertinent for 
Caucasian population. 
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